Edition:
India

Aldeyra Therapeutics Announces Positive Results From Phase 2B Dry Eye Disease Clinical Trial


Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PHASE 2B DRY EYE DISEASE CLINICAL TRIAL.ALDEYRA THERAPEUTICS INC - PIVOTAL CLINICAL TESTING EXPECTED TO BEGIN IN 2019 FOLLOWING DISCUSSION WITH REGULATORY AUTHORITIES.ALDEYRA THERAPEUTICS INC - STATISTICALLY SIGNIFICANT IMPROVEMENT ACROSS MULTIPLE SYMPTOM AND SIGN MEASURES.ALDEYRA THERAPEUTICS INC - EARLY ONSET AND BROAD RANGE OF ACTIVITY SUPPORTS DIFFERENTIATED PRODUCT PROFILE.ALDEYRA - CONSISTENT WITH PREVIOUS CLINICAL TRIALS, TOPICAL OCULAR REPROXALAP WAS WELL TOLERATED, AND REPORTED ADVERSE EVENTS WERE GENERALLY MILD.